MetLife Investment Management LLC Invests $146,000 in Alto Neuroscience, Inc. (NYSE:ANRO)

MetLife Investment Management LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,783 shares of the company’s stock, valued at approximately $146,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ANRO. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience during the first quarter worth approximately $8,233,000. Bowie Capital Management LLC acquired a new stake in Alto Neuroscience during the second quarter worth approximately $462,000. Jennison Associates LLC raised its holdings in Alto Neuroscience by 80.3% in the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after acquiring an additional 370,612 shares in the last quarter. TD Asset Management Inc bought a new stake in shares of Alto Neuroscience during the 2nd quarter valued at $928,000. Finally, Rhumbline Advisers acquired a new stake in shares of Alto Neuroscience during the 2nd quarter worth $113,000.

Analyst Upgrades and Downgrades

ANRO has been the subject of a number of analyst reports. RODMAN&RENSHAW downgraded Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus reduced their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Alto Neuroscience Trading Down 5.4 %

Shares of NYSE:ANRO opened at $3.70 on Tuesday. Alto Neuroscience, Inc. has a one year low of $3.61 and a one year high of $24.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The firm has a 50 day simple moving average of $6.88 and a 200 day simple moving average of $10.22.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. As a group, research analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.